Matches in SemOpenAlex for { <https://semopenalex.org/work/W2087718210> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W2087718210 abstract "The purpose of these studies was to evaluate the effect of lerisetron (1-phenyl-methyl-2-piperazinyl-1H-benzimidazole hydrochloride, CAS 143257-98-1, F-0930-RS2), a new 5-HT3 receptor antagonist, on ipecacuanha-induced nausea and vomiting. The ipecacuanha model of emesis has been used to test the anti-emetic activity of several different 5-HT3 antagonists and the anti-emetic doses that were effective in the ipecacuanha model have been found to correlate well with the clinically effective doses. Study 1 investigated oral doses of lerisetron from 4 mg to 40 mg. Study 2 evaluated the duration of effect of a single dose of 20 mg oral lerisetron. Study 3 evaluated intravenous doses of 18 mg and 12 mg lerisetron. In Study 1, the 40 mg dose of oral lerisetron inhibited emesis in all test subjects. The percentage of subjects who experienced an emetic episode increased as the dose of lerisetron decreased. At the lowest dose level tested five of six subjects had an emetic episode compared with four out of five in the placebo group. In Study 2, 20 mg oral lerisetron was effective up to 12 h after administration. When ipecacuanha was administered at 18 h post-dose three of seven subjects had an emetic episode and at 24 h post-dose the incidence of emesis was similar to the placebo treatment groups in the previous study. Study 3 demonstrated the effectiveness of intravenous doses of lerisetron. The 18 mg intravenous dose reduced the number of patients experiencing emetic episodes by 75% compared with placebo, doses below 12 mg i.v. were not evaluated because of the reduced efficacy of the compound at this dose level. In conclusion, lerisetron has been shown to be effective in the treatment of ipecacuanha-induced nausea and vomiting at intravenous doses of 18 mg and at oral doses of 20 mg for up to 12 hours." @default.
- W2087718210 created "2016-06-24" @default.
- W2087718210 creator A5015841967 @default.
- W2087718210 creator A5048325460 @default.
- W2087718210 creator A5059841969 @default.
- W2087718210 creator A5062670268 @default.
- W2087718210 date "2011-12-26" @default.
- W2087718210 modified "2023-09-26" @default.
- W2087718210 title "Effects of Lerisetron, a New 5-HT3 Receptor Antagonist, on Ipecacuanha- induced Emesis in Healthy Volunteers" @default.
- W2087718210 doi "https://doi.org/10.1055/s-0031-1299952" @default.
- W2087718210 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12404884" @default.
- W2087718210 hasPublicationYear "2011" @default.
- W2087718210 type Work @default.
- W2087718210 sameAs 2087718210 @default.
- W2087718210 citedByCount "2" @default.
- W2087718210 countsByYear W20877182102020 @default.
- W2087718210 crossrefType "journal-article" @default.
- W2087718210 hasAuthorship W2087718210A5015841967 @default.
- W2087718210 hasAuthorship W2087718210A5048325460 @default.
- W2087718210 hasAuthorship W2087718210A5059841969 @default.
- W2087718210 hasAuthorship W2087718210A5062670268 @default.
- W2087718210 hasConcept C126322002 @default.
- W2087718210 hasConcept C142724271 @default.
- W2087718210 hasConcept C170493617 @default.
- W2087718210 hasConcept C204787440 @default.
- W2087718210 hasConcept C27081682 @default.
- W2087718210 hasConcept C2776885963 @default.
- W2087718210 hasConcept C2777056448 @default.
- W2087718210 hasConcept C2780580376 @default.
- W2087718210 hasConcept C2780852908 @default.
- W2087718210 hasConcept C2780884295 @default.
- W2087718210 hasConcept C42219234 @default.
- W2087718210 hasConcept C71924100 @default.
- W2087718210 hasConcept C98274493 @default.
- W2087718210 hasConceptScore W2087718210C126322002 @default.
- W2087718210 hasConceptScore W2087718210C142724271 @default.
- W2087718210 hasConceptScore W2087718210C170493617 @default.
- W2087718210 hasConceptScore W2087718210C204787440 @default.
- W2087718210 hasConceptScore W2087718210C27081682 @default.
- W2087718210 hasConceptScore W2087718210C2776885963 @default.
- W2087718210 hasConceptScore W2087718210C2777056448 @default.
- W2087718210 hasConceptScore W2087718210C2780580376 @default.
- W2087718210 hasConceptScore W2087718210C2780852908 @default.
- W2087718210 hasConceptScore W2087718210C2780884295 @default.
- W2087718210 hasConceptScore W2087718210C42219234 @default.
- W2087718210 hasConceptScore W2087718210C71924100 @default.
- W2087718210 hasConceptScore W2087718210C98274493 @default.
- W2087718210 hasLocation W20877182101 @default.
- W2087718210 hasLocation W20877182102 @default.
- W2087718210 hasOpenAccess W2087718210 @default.
- W2087718210 hasPrimaryLocation W20877182101 @default.
- W2087718210 hasRelatedWork W1967763477 @default.
- W2087718210 hasRelatedWork W1971199372 @default.
- W2087718210 hasRelatedWork W1971284925 @default.
- W2087718210 hasRelatedWork W1972267682 @default.
- W2087718210 hasRelatedWork W1972704535 @default.
- W2087718210 hasRelatedWork W2004021220 @default.
- W2087718210 hasRelatedWork W2019410852 @default.
- W2087718210 hasRelatedWork W2026194749 @default.
- W2087718210 hasRelatedWork W2035639051 @default.
- W2087718210 hasRelatedWork W2042926768 @default.
- W2087718210 hasRelatedWork W2057663094 @default.
- W2087718210 hasRelatedWork W2058514250 @default.
- W2087718210 hasRelatedWork W2143767990 @default.
- W2087718210 hasRelatedWork W2146545343 @default.
- W2087718210 hasRelatedWork W2170081289 @default.
- W2087718210 hasRelatedWork W2389836637 @default.
- W2087718210 hasRelatedWork W2406758301 @default.
- W2087718210 hasRelatedWork W2413586587 @default.
- W2087718210 hasRelatedWork W2433987881 @default.
- W2087718210 hasRelatedWork W2434789454 @default.
- W2087718210 isParatext "false" @default.
- W2087718210 isRetracted "false" @default.
- W2087718210 magId "2087718210" @default.
- W2087718210 workType "article" @default.